Time filter

Source Type

Gao M.-Y.,Childrens Hospital of Hebei Province | Jie L.,Peoples Hospital of Hebei Province | Zhang W.-X.,Childrens Hospital of Hebei Province
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2010

BACKGROUND: Hyperplastic scar is the abnormal results of wound healing, which severely effects body appearance and leads to functional disturbance. OBJECTIVE: To review the prevention and treatment of hypertrophic scar status in China and abroad. METHODS: PubMed, Embase, Chinese Biomedical Literature Database, CNKI, CAJ were retrieved by computer with key words of "hypertrophic scars, prevention and treatment". The language was limited for English and Chinese. Simultaneously, related monograph was manually searched. The studies regarding biological features of hypertrophic scar, reasons for hypertrophic scar formation, as well as prevention and treatment of hypertrophic scar were included in the analysis. RESULTS AND CONCLUSION: The main causes of hypertrophic scar fibroblasts are biological characteristics of abnormal increase in the number of fibroblasts. A large number of collagen fibers synthesized and secreted is the key to the formation of scar tissue. The prevention and treatment of hypertrophic scar should be integrated early in wound healing to take preventive measures to curb scar. Treatment should be combined in several ways to take combination therapy, which received notable results compared with monotherapy. In addition, in recent years the role of Chinese medicine in the mechanism of scar formation, animal experiments and dose reconstruction studies are endless. Strengthening of Chinese medicine in prevention and treatment of hypertrophic scar research is very important. The occurrence and development of abnormal scars should be thoroughly avoided or reduced from the source, genetic level defects should be amended to prevent and treat hypertrophic scars. Traditional Chinese medicine can be a further breakthrough in the prevention and treatment of hypertrophic scars.

Zhu Y.,PLA Fourth Military Medical University | Zhang G.,PLA Fourth Military Medical University | Zhao J.,PLA Fourth Military Medical University | Li D.,PLA Fourth Military Medical University | And 13 more authors.
Clinical Drug Investigation | Year: 2013

Background and Objective: Mildronate, an inhibitor of carnitine-dependent metabolism, is considered to be an anti-ischemic drug. This study is designed to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke. Methods: We performed a randomized, double-blind, multicenter clinical study of mildronate injection for treating acute cerebral infarction. 113 patients in the experimental group received mildronate injection, and 114 patients in the active-control group received cinepazide injection. In addition, both groups were given aspirin as a basic treatment. Modified Rankin Scale (mRS) score was performed at 2 weeks and 3 months after treatment. National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score were performed at 2 weeks after treatment, and then vital signs and adverse events were evaluated. Results: A total of 227 patients were randomized to treatment (n = 113, mildronate; n = 114, active-control). After 3 months, there was no significant difference for the primary endpoint between groups categorized in terms of mRS scores of 0-1 and 0-2 (p = 0.52 and p = 0.07, respectively). There were also no significant differences for the secondary endpoint between groups categorized in terms of NIHSS scores of >5 and >8 (p = 0.98 and p = 0.97, respectively) or BI scores of >75 and >95 (p = 0.49 and p = 0.47, respectively) at 15 days. The incidence of serious adverse events was similar between the two groups. Conclusion: Mildronate injection is as effective and safe as cinepazide injection in treating acute cerebral infarction. © 2013 Springer International Publishing Switzerland.

Fan F.,Peoples Hospital of Hebei Province | Li Y.,2nd Peoples Hospital of Yunnan Province | Duan X.,Central South University | Zhao T.,Central South University | And 2 more authors.
Graefe's Archive for Clinical and Experimental Ophthalmology | Year: 2012

Purpose To investigate the influence of rosiglitazone on activation of human Tenon's fibroblasts (HTFs) and to access the possible mechanism. Methods Cultured human Tenon's fibroblasts were pretreated in two different concentrations of rosiglitazone (5 μmol/l and 10 μmol/l) before being stimulated with 5 ng/ml transforming growth factor β1 (TGF-β1). The viability and proliferation of cells were accessed by cell count kit-8 assay; Cell migration was examined by the wound closure assay; Alpha smooth muscle actin (α-SMA), connective tissue growth factor (CTGF) and type I collagen (COL I) transcription were detected by RT-qPCR; The expression and localization of α-SMA protein were examined by Western-blot analysis and Immunofluorescence staining; Western-blot analysis was also used to check the expression of CTGF, COL I peroxisome proliferatoractivated receptor gamma (PPAR-γ), and phosphorylation of the signaling protein Smad2/3 Results Rosiglitazone is able to attenuate the up-regulation of α-SMA, CTGF, and COL I transcription, as well as affect protein expression, proliferation, and migration of cells; rosiglitazone also can increase PPAR-γ expression and attenuate Smad2/3 phosphorylation. Conclusions Rosiglitazone can effectively attenuate activation of HTFs induced by TGF-β1 without obvious toxicity. The possible mechanism might be that rosiglitazone interferes with TGF-β/Smad signaling pathway. © Springer-Verlag 2012.

Hao L.-N.,Peoples Hospital of Hebei Province | Zhang Y.-Q.,Chengde County Hospital | Shen Y.-H.,Eye Hospital of Handan | Wang Z.-Y.,Chengde County Hospital | And 3 more authors.
International Journal of Ophthalmology | Year: 2010

AIM: To evaluate the peroxy nitrite (ONOO-) of puerarin on retinal pigment epithelial (RPE) cells apoptosis induced partly by peroxy nitrite via Fas/FasL. METHODS: RPE cells from CBL/6 m ice eyes were cultured. Diabetes was induced in Sprague-Dawley (SD) rats by streptozotocin (STZ) intraperitoneal injection. Puerarin was adm inistrated to cultured RPE cells and diabetic rats. Western blotting analysis, DNA ladder, RT-PCR, immuno histochemistry were used for determining the expression of nitroty rosine (NT, the foot print of ONOO-), complement 3 (C; apoptosis and inducible nitricoxide synthase (iNOS) m RNA as well as Fas/FasL signal transduction in RPE cells. RESULTS: Both RPE cells in ONOO- and puerarin group developed apoptosis and expressed NT, C3, iNOS m RNA and Fas/FasL. But latter delayed the all changes in a time-dependent manner compared with control and STZ group (P<0.001 ). iNOS, Cand Fas/FasL were up-regulated and associated with an increase of expression of ONOO- in vivo and in vitro. CONCLUSION: Puerarin decreases RPE cells apoptosis partly induced by ONOO- for diabetic retinopathy. ©International Journal of Ophthalmology Press.

Yao W.,Peking University | Wang C.,Chongqing Medical University | Zhong N.,Guangzhou Institute of Respiratory Disease | Han X.,Peoples Hospital of Hebei Province | And 6 more authors.
Respirology | Year: 2014

Background and objective This study, in a predominantly Chinese population, investigated the efficacy and safety of a once-daily (o.d.) inhaled ultra-long-acting β2-agonist indacaterol for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). Methods This is a 26-week, double-blind study on randomized patients who received indacaterol 150 μg or 300 μg or placebo o.d. The primary variable was trough forced expiratory volume in 1 s (FEV1, average of 23 h 10 min and 23 h 45 min post-dose values) at Week 12. Health status (St George's Respiratory Questionnaire, SGRQ), dyspnoea (transition dyspnoea index, TDI) and safety were evaluated over 26 weeks. Results Of the 563 patients randomized, 561 (89.8% Chinese) received treatment and 482 completed. At Week 12, trough FEV 1 improved significantly for indacaterol 150 and 300 μg versus placebo (1.32, 1.29 vs 1.17; P < 0.001 for both comparisons), with differences exceeding the pre-specified minimal clinically important difference of 0.12 L. At Week 26, TDI score was superior to placebo for indacaterol 150 and 300 μg (0.82, 1.15; P < 0.01), as was the percentage of patients with a clinically relevant improvement (≥1 point) (74.1%, 78.6% vs 55.5%; P < 0.05). Both doses provided ≥4-point improvements from baseline in SGRQ score at Week 26 that were numerically greater than placebo (unadjusted means: -9.6, -8.8 vs -7.0), with a similar pattern in percentage of patients with clinically relevant improvements in SGRQ score (65.0%, 61.5% vs 60.6%). Incidences of adverse events were comparable across treatment groups. Conclusions Indacaterol delivered effective bronchodilation with significant improvements in breathlessness and health status in this predominantly Chinese population. We investigated the effect of indacaterol on FEV1, dyspnoea and health-related quality of life in a predominantly Chinese population diagnosed with moderate-to-severe COPD. Indacaterol proved to be a useful treatment option as it showed effective bronchodilation and improvements in breathlessness and health status in this population. © 2014 The Authors. Respirology © 2014 Asian Pacific Society of Respirology.

Discover hidden collaborations